Can a maintenance drug keep myeloma at bay?
NCT ID NCT02538198
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug lenalidomide, taken as maintenance therapy, can delay the return of multiple myeloma in patients who have already responded to initial treatment. Participants take lenalidomide daily and are monitored for how long they remain free of disease progression. The goal is to see if this approach extends remission without causing unacceptable side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lenalidomide
- What this could lead to
- If successful, this could show that lenalidomide maintenance helps keep myeloma in remission longer after initial treatment.
- What could go wrong
- This is a mid-stage trial with a moderate number of participants, so results may not be definitive. Lenalidomide can cause side effects like fatigue, low blood counts, and increased risk of infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- Could a tiny dose of radiation ease myeloma bone pain?
- Could a common allergy pill ease bone pain in myeloma treatment?
- New vaccine aims to train immune system against myeloma
- Multiple myeloma patients get continued access to isatuximab in safety extension study
- Promising drug cocktail aims to hold multiple myeloma at bay longer